Neuraxpharm Enters Japanese Market
Follows Buccolam Deal With Takeda Last Year
Executive Summary
Neuraxpharm has expanded its footprint outside of Europe with the launch of its first product in Japan, in the form of the Buccolam value-added midazolam product gained through a deal with Takeda.
You may also be interested in...
Medinutrix Acquisition Gives Neuraxpharm Gateway To Ireland
Neuraxpharm will gain a platform in Ireland after striking a deal to acquire local distribution specialist Medinutrix.
Neuraxpharm Snapped Up By Private Equity In Europe’s Largest Deal
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.
Neuraxpharm Buccolam Acquisition Opens Up Opportunities
Neuraxpharm says a deal with Takeda to acquire the only buccal midazolam approved across Europe, Buccolam, not only gives the CNS specialist a strong asset but also offers the opportunity to expand its commercial footprint into the Nordics and Ireland.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: